Novel herbal composition for the treatment of gastric ulcer

ABSTRACT

The present invention provides a synergistic herbal composition for the treatment of gastric ulcer, said composition essentially comprising of powdered plant parts of  Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum  and  Trachyaparmum roxburghicinum  and optionally, powdered plant parts of  Cyclea peltate, Embelia ribes, Coriandrum sativum Ferula asafoetida, Aloe barbadensis  and  Evolvulus aisinodes  along with one or more pharmaceutically acceptable additives/carriers, a process for preparing said composition and method for treating gastric ulcer using said composition.

FIELD OF THE INVENTION

The present invention relates to a novel synergistic herbal compositionfor the treatment of gastric ulcer. The present invention also relatesto a method for the preparation of the composition. The presentinvention further relates to a process for the treatment of gastriculcer using the composition.

BACKGROUND AND PRIOR ART TO THE INVENTION

Various theories have been proposed with respect to a cause of ulcer inhuman. In particular, it has been elucidated that stress, taking ofnon-steroidal anti-inflammatory drugs for curing rheumatic diseases, andthe like are closely related to ulcer formation, mainly due torelatively excess gastric or duodenal acid secretion. Accordingly it isimportant to suppress the acid secretion in order to prevent ulcerformation and to cure it.

On the other hand it has been considered that Helicobacter pylori, whichis a rod normally existing in stomach, generates ammonia due to itsstrong urease activity, thereby inducing ulcer. Since, it persistentlylives within mucus and mucosa, it becomes the greatest cause forrecurrence of ulcer. Accordingly, it has been considered that therecurrence of ulcer can be prevented, if this bacterium is sterilized.

References may be made to K. M. Nadkarni in Indian Materia Medica (1976)Vol. 1, p 74-76, 155, published by Popular Prakashan Pvt. Ltd., Mumbai;K. R. Kirtikar in Indian Medicinal Plants (1975) Vol. 4, p 2505published by Bishen Singh Mahendrapal Singh, Dehradun and P. K. Warrierin Indian Medicinal Plants-A compendium of 500 species (1994-1996) Vol.1, p 103 for the various medicinal properties of Aloe barbadensis.

References may be made to K. M. Nadkarni in Indian Materia Medica (1976)Vol. 1, p 155 published by Popular Prakashan Pvt. Ltd., Mumbai; K. R.Kirtikar in Indian Medicinal Plants (1975) Vol. 4, p 2249 published byBishen Singh Mahendrapal Singh, Dehradun; P. K. Warrier in IndianMedicinal Plants-A compendium of 500 species (1994-1996) Vol. 1, p 218,and K. Narayana Iyer and M. Kolammal in Pharmacognosy of Ayurvedic Drugs(1963) Series 1, No. 6, p. 48 published by Department of Pharmacognosy,University of Kerala, Trivandrum for the various medicinal properties ofAsperagus racemosus. References may be made to K. M. Nadkarni in IndianMateria Medica (1976) Vol. 1, p 582 published by Popular Prakashan Pvt.Ltd., Mumbai; K. R. Kirtikar in Indian Medicinal Plants (1975) Vol. 1,p. 728 published by Bishen Singh Mahendrapal Singh, Dehradun; P. K.Warrier in Indian Medicinal Plants-A compendium of 500 species (19941996) Vol. 3, p 84, 86-87; The Wealth of India (1950-1980) Vol. 4, p.152-153, published by Council of Scientific and Industrial Research; S.S. Handa in Indian Herbal Pharmacopeia (1998), p. 96, published byRegional Research Laboratory, Jammu and IDMA, Mumbai; Y. K. Sarin inIllustrated lanual of herbal drugs used in Ayurveda (1996), p. 116, andThe Ayurvedic Pharmacopoeia of India, Vol. 1, p. 128, published byMinistry of Health and Family Welfare, India for the various medicinalproperties of Glychyrrhiza glabra.

References may be made to K. M. Nadkarni in Indian Materia Medica (1976)Vol. 1, p. 1127-28, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 3, p 1858-89published by Bishen Singh Mahendrapal Singh, Dehradun; P. K. Warrier inIndian Medicinal Plants-A compendium of 500 species (1994-1996) Vol. 5,p 104, and The Wealth of India (1950-1980) Vol. 9, p. 290, published byCouncil of Scientific and Industrial Research for the various medicinalproperties of Seaamum indicum.

References may be made to K. M. Nadkarni in Indian Materia Medica (1976)Vol. 1, p 531, published by Popular Prakashan Pvt. Ltd., Mumbai; P. K.Warrier in Indian Medicinal Plants-A compendium of 500 species(1994-1996) Vol. 3, p. 11-12, and K. Narayana Iyer and M. Kolammal inPharmacognosy of Ayurvedic Drugs (1963) Series 1, No. 6, p. 1, publishedby Department of Pharmacognosy, University of Kerala, Trivandrum for thevarious medicinal properties of Evolvulus aisinodes.

References may be made to K. M. Nadkarni in Indian Materia Medica (1976)Vol. 1, p822-825, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 4, p. 2454, publishedby Bishen Singh Mahendrapal Singh, Dehradun, and P. K. Warrier in IndianMedicinal Plants-A compendium of 500 species (1994-1996) Vol. 4, p 78for the various medicinal properties of Musa sapientum.

References may be made to K. M. Nadkarni in Indian Materia Medica (1976)Vol. 1, p 1028-1030, published by Popular Prakashan Pvt. Ltd., Mumbai;P. K. Warrier in Indian Medicinal Plants-A compendium of 500 species(1994-1996) Vol. 3, p. 299, published by orient Longman, Chennai; TheWealth of India (1950-1980) Vol. 10, p. 271, published by Council ofScientific and Industrial Research; Y. K. Sarin in Illustrated lanual ofherbal drugs used in Ayurveda (1996), p. 202, and The AyurvedicPharmacopoeia of India, Vol. 1, p. 3, published by Ministry of Healthand Family Welfare, India for the various medicinal properties ofTrachyaparmum roxburghicinum.

References may be made to K. M. Nadkarni in Indian Materia Medica (1976)Vol. 1, p. 478, published by Popular Prakashan Pvt. Ltd., Mumbai; K. R.Kirtikar in Indian Medicinal Plants (1975) Vol. 2, p. 1479, published byBishen Singh Mahendrapal Singh, Dehradun; P. K. Warrier in IndianMedicinal Plants-A compendium of 500 species (1994-1996) Vol. 2, p. 368,published by orient Longman, Chennai; The Wealth of India (1950-1980)Vol. 3, p. 167, published by Council of Scientific and IndustrialResearch; Y. K. Sarin in Illustrated lanual of herbal drugs used inAyurveda (1996), p. 290, and The Ayurvedic Pharmacopoeia of India, Vol.1, p. 124, published by Ministry of Health and Family Welfare, India forthe various medicinal properties of Embelia ribes.

References may be made to K. M. Nadkarni in Indian Materia Medica (1976)Vol. 1, p. 381-82, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 2, p. 1225, publishedby Bishen Singh Mahendrapal Singh, Dehradun; P. K. Warrier in IndianMedicinal Plants-A compendium of 500 species (1994-1996) Vol. 2, p. 184,published by orient Longman, Chennai, and The Wealth of India(1950-1980) Vol. 3, p. 349, published by Council of Scientific andIndustrial Research for the various medicinal properties of Coriandrumsativum.

Reference may be made to P. K. Warrier in Indian Medicinal Plants-Acompendium of 500 species (1994-1996) Vol. 2, p. 277, published byorient Longman for the various medicinal properties of Cyclea peltate.

References may be made to K. M. Nadkarni in Indian Materia Medica (1976)Vol. 1, p. 537, published by Popular Prakashan Pvt. Ltd., Mumbai; K. R.Kirtikar in Indian Medicinal Plants (1975) Vol. 2, p. 1217, published byBishen Singh Mahendrapal Singh, Dehradun; P. K. Warrier in IndianMedicinal Plants-A compendium of 500 species (1994-1996) Vol. 3, p. 13,published by orient Longman, Chennai; Y. K. Sarin in Illustrated lanualof herbal drugs used in Ayurveda (1996), p. 332, and The AyurvedicPharmacopoeia of India, p. 50, published by Ministry of Health andFamily Welfare, India for the various medicinal properties of Ferulaasafoetida.

The composition of the present invention should not be treated as anobvious one as none of the citations are able to provide all theadvantages of the present invention.

OBJECTS OF THE INVENTION

The main object of the present invention is to provide a novelsynergistic herbal composition for the treatment of gastric ulcer.

Yet another object of the present invention is to provide a process forthe preparation of the composition.

Still another object of the present invention is to provide a method forthe treatment of gastric ulcer using the composition.

SUMMARY OF THE INVENTION

The present invention provides a novel synergistic herbal compositionfor the treatment of gastric ulcer. Also, the present invention providesa process for the preparation of the composition. The present inventionfurther provides a method for the treatment of gastric ulcer using saidcomposition.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

In accordance with the first embodiment of the present invention, thereis provided a synergistic herbal composition for the treatment ofgastric ulcer, said composition essentially comprising of powdered plantparts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musasapientum and Trachyaparmum roxburghicinum and optionally, powderedplant parts of Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferulaasafoetida, Aloe barbadensis and Evolvulus aisinodes along with one ormore pharmaceutically acceptable additives/carriers.

In an embodiment of the present invention, the composition comprisespowdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamumindicum, Musa sapientum and Trachyaparmum roxburghicinum in equalproportions, optionally along with one or more pharmaceuticallyacceptable additives/carriers. This composition is hereafter referred toas HF3.

In another embodiment of the present invention, the compositioncomprises powdered plant parts of Asperagus racemosus, Glycyrrhizaglabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum,Evolvulus aisinodes and Ferula asafoetida in equal proportions,optionally along with one or more pharmaceutically acceptableadditives/carriers. This composition is hereafter referred to as HF4.

In yet another embodiment of the present invention, the compositioncomprises powdered plant parts of Asperagus racemosus, Glycyrrhizaglabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum,Evolvulus alsinodes, Ferula asafoetida, Coriandrum sativum, Cycleapeltate and Aloe barbadensis in equal proportions, optionally along withone or more pharmaceutically acceptable additives/carriers. Thiscomposition is hereafter referred to as HF5.

In still another embodiment of the present invention, the compositioncomprises 5-13 wt. % of powdered plant parts of Asperagus racemosus,5-12 wt. % of powdered plant parts of Glycyrrhiza glabra, 8-14 wt. % ofpowdered plant parts of Seaamum indicum, 7-14 wt. % of powdered plantparts of Musa sapientum, 4-12 wt. % of powdered plant parts ofTrachyaparmum roxburghicinum, 6-12 wt. % of powdered plant parts of Aloebarbadensis, 12 wt. % of powdered plant parts of Evolvulus aisinodes,6-13 wt. % of powdered plant parts of Cyclea peltate, 9-14 wt. % ofpowdered plant parts of Embelia ribes, 7-14 wt. % of powdered plantparts of Coriandrum sativum and 8-13 wt. % of plant parts of Ferulaasafoetida, optionally along with one or more pharmaceuticallyacceptable additives/carriers. This composition is hereafter referred toas HF2.

In one more embodiment of the present invention, the plant part ofTrachyaparmum roxburghicinum, Embelia ribes and Coriandrum sativum isfruit.

In one another embodiment of the present invention, the plant part ofCyclea peltate and Glycyrrhiza glabra is root.

In a further embodiment of the present invention, the plant part of Aloebarbadensis is elio. In a furthermore embodiment of the presentinvention, the plant part of Asperagus racemosus is tuber.

In an embodiment of the present invention, the plant part of Seaamumindicum is seed.

In another embodiment of the present invention, the plant part of Musasapientum is unripe fruit.

In yet another embodiment of the present invention, the plant part ofFerula asafoetida is resin.

In accordance with the another embodiment of the present invention,there is provided a synergistic herbal composition for the treatment ofgastric ulcer, said composition comprising equal proportions of 10powdered plant parts selected from the group comprising of powderedplant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum,Musa sapientum, Trachyaparmum roxburghicinum, Cyclea peltate, Embeliaribes, Coriandrum sativum, Ferula asafoetida, Aloe barbadensis andEvolvulus aisinodes, optionally along with one or more pharmaceuticallyacceptable additives/carriers.

In an embodiment of the present invention, said composition comprisesequal proportions of powdered plant parts of Asperagus racemosus,Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmumroxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum,Ferula asafoetida and Aloe barbadensis, optionally along with one ormore pharmaceutically acceptable additives/carriers.

In another embodiment of the present invention, said compositioncomprises equal proportions of powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum,Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Coriandrumsativum, Ferula asafoetida and Evolvulus aisinodes, optionally alongwith one or more pharmaceutically acceptable additives/carriers.

In yet another embodiment of the present invention, said compositioncomprises equal proportions of powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum,Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Coriandrumsativum, Aloe barbadensis and Evolvulus aisinodes, optionally along withone or more pharmaceutically acceptable additives/carriers.

In still another embodiment of the present invention, said compositioncomprises equal proportions of powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum,Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Ferulaasafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally alongwith one or more pharmaceutically acceptable additives/carriers.

In one more embodiment of the present invention, said compositioncomprises equal proportions of powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum,Trachyaparmum roxburghicinum, Cyclea peltate, Coriandrum sativum, Ferulaasafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally alongwith one or more pharmaceutically acceptable additives/carriers.

In one another embodiment of the present invention, said compositioncomprises equal proportions of powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum,Trachyaparmum roxburghicinum, Embelia ribes, Coriandrum sativum, Ferulaasafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally alongwith one or more pharmaceutically acceptable additives/carriers.

In a further embodiment of the present invention, said compositioncomprises equal proportions of powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Cycleapeltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida, Aloebarbadensis and Evolvulus aisinodes, optionally along with one or morepharmaceutically acceptable additives/carriers.

In a further more embodiment of the present invention, said compositioncomprises equal proportions of powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Seaamum indicum, Trachyaparmumroxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum,Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionallyalong with one or more pharmaceutically acceptable additives/carriers.

In an embodiment of the present invention, said composition comprisesequal proportions of powdered plant parts of Asperagus racemosus,Glycyrrhiza glabra, Musa sapientum, Trachyaparmum roxburghicinum, Cycleapeltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida, Aloebarbadensis and Evolvulus aisinodes, optionally along with one or morepharmaceutically acceptable additives/carriers.

In another embodiment of the present invention, said compositioncomprises equal proportions of powdered plant parts of Asperagusracemosus, Seaamum indicum, Musa sapientum, Trachyaparmumroxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum,Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionallyalong with one or more pharmaceutically acceptable additives/carriers.

In yet another embodiment of the present invention, said compositioncomprises equal proportions of powdered plant parts of Glycyrrhizaglabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum,Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida,Aloe barbadensis and Evolvulus aisinodes, optionally along with one ormore pharmaceutically acceptable additives/carriers.

In accordance with the second embodiment of the present invention, thereis provided a process for the preparation of the novel synergisticherbal composition for the treatment of gastric ulcer, said processcomprising the steps of powdering plant parts essentially selected fromAsperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientumand Trachyaparmum roxburghicinum and optionally, selected from Cycleapeltate, Embelia ribes, Coriandrum sativum Ferula asafoetida, Aloebarbadensis and Evolvulus aisinodes, mixing the aforesaid powdered plantparts to obtain a mixture and optionally adding one or morepharmaceutically acceptable additives/carriers to the above mixture.

In an embodiment of the present invention, said process comprises thesteps of powdering plant parts of Asperagus racemosus, Glycyrrhizaglabra, Seaamum indicum, Musa sapientum and Trachyaparmumroxburghicinum, mixing the aforesaid plant parts in equal proportions toobtain a mixture and optionally adding one or more pharmaceuticallyacceptable additives/carriers to the above mixture.

In another embodiment of the present invention, said process comprisesthe steps of powdering plant parts of Asperagus racemosus, Glycyrrhizaglabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum,Evolvulus aisinodes and Ferula asafoetida, mixing the aforesaid plantparts in equal proportions to obtain a mixture and optionally adding oneor more pharmaceutically acceptable additives/carriers to the abovemixture.

In yet another embodiment of the present invention, said processcomprises steps of powdering plant parts of Asperagus racemosus,Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmumroxburghicinum, Evolvulus alsinodes, Ferula asafoetida, Coriandrumsativum, Cyclea peltate and Aloe barbadensis, mixing the aforesaid plantparts in equal proportions to obtain a mixture and optionally adding oneor more pharmaceutically acceptable additives/carriers to the abovemixture.

In still another embodiment of the present invention, said processcomprises the steps of powdering and mixing 5-13 wt. % of plant parts ofAsperagus racemosus, 5-12 wt. % of plant parts of Glycyrrhiza glabra,8-14 wt. % of plant parts of Seaamum indicum, 7-14 wt. % of plant partsof Musa sapientum, 4-12 wt. % of plant parts of Trachyaparmumroxburghicinum, 6-12 wt. % of plant parts of Aloe barbadensis, 5-12 wt.% of plant parts of Evolvulus aisinodes, 6-13 wt. % of plant parts ofCyclea peltate 9-14 wt. % of plant parts of Embelia ribes, 7-14 wt. % ofplant parts of Coriandrum sativum and 8-13 wt. % of plant parts ofFerula asafoetida to obtain a mixture and optionally adding one or morepharmaceutically acceptable additives/carriers to the above mixture.

In one more embodiment of the present invention, the plant part ofTrachyaparmum roxburghicinum, Embelia ribes and Coriandrum sativum isfruit.

In one another embodiment of the present invention, the plant part ofCyclea peltate and Glycyrrhiza glabra is root.

In a further embodiment of the present invention, the plant part of Aloebarbadensis is elio.

In a furthermore embodiment of the present invention, the plant part ofAsperagus racemosus is tuber.

In an embodiment of the present invention, the plant part of Seaamumindicum is seed.

In another embodiment of the present invention, the plant part of Musasapientum is unripe fruit.

In yet another embodiment of the present invention, the plant part ofFerula asafoetida is resin.

In accordance with another object of the present invention, there isprovided a method of treating gastric ulcer in a subject, said methodcomprising administering an effective amount of the synergistic herbalcomposition essentially comprising of powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum andTrachyaparmum roxburghicinum and optionally, powdered plant parts ofCyclea peltate, Embelia ribes, Coriandrum sativum Ferula asafoetida,Aloe barbadensis and Evolvulus aisinodes along with one or morepharmaceutically acceptable additives/carriers. In an embodiment of thepresent invention, said method comprises administering an effectiveamount of the synergistic herbal composition comprising of powderedplant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum,Musa sapientum and Trachyaparmum roxburghicinum in equal proportions,optionally along with one or more pharmaceutically acceptableadditives/carriers.

In another embodiment of the present invention, said method comprisesadministering an effective amount of the synergistic herbal compositioncomprising of powdered plant parts of Asperagus racemosus, Glycyrrhizaglabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum,Evolvulus aisinodes and Ferula asafoetida in equal proportions,optionally along with one or more pharmaceutically acceptableadditives/carriers.

In yet another embodiment of the present invention, said methodcomprises administering an effective amount of the synergistic herbalcomposition comprising of powdered plant parts of Asperagus racemosus,Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmumroxburghicinum, Evolvulus alsinodes, Ferula asafoetida, Coriandrumsativum, Cyclea peltate and Aloe barbadensis in equal proportions,optionally along with one or more pharmaceutically acceptableadditives/carriers.

In still another embodiment of the present invention, said methodcomprises administering an effective amount of the synergistic herbalcomposition comprising 5-13 wt. % of powdered plant parts of Asperagusracemosus, 5-12 wt. % of powdered plant parts of Glycyrrhiza glabra,8-14 wt. % of powdered plant parts of Seaamum indicum, 7-14 wt. % ofpowdered plant parts of Musa sapientum, 4-12 wt. % of powdered plantparts of Trachyaparmum roxburghicinum, 6-12 wt. % of powdered plantparts of Aloe barbadensis, 5-12 wt. % of powdered plant parts ofEvolvulus aisinodes, 6-13 wt. % of powdered plant parts of Cycleapeltate 9-14 wt. % of powdered plant parts of Embelia ribes, 7-14 wt. %of powdered plant parts of Coriandrum sativum and 8-13 wt. % of plantparts of Ferula asafoetidain equal proportions, optionally along withone or more pharmaceutically acceptable additives/carriers.

In one more embodiment of the present invention, the subject is a mammalincluding human.

In one another embodiment of the present invention, the effective dosageof the composition per day is in the range of 5 to 15 g.

In a further embodiment of the present invention, the composition can bein the form of tablets, capsules, syrup and any other conventionalforms.

In a furthermore embodiment of the present invention, the composition isadministered orally, intramuscularly, and by any other conventionalmethods.

In an embodiment of the present invention, the composition may be usedfor therapeutic as well as prophylactic treatment of gastric ulcer.

In another embodiment of the present invention, the subject may beadministered a bolus dose or a multiple dose.

In yet another embodiment of the present invention, wherein thecomposition HF2 showed more than 62% protection against cold restraintulcer model.

In still another embodiment of the present invention, wherein thecomposition HF2 showed more than 30% protection against aspirin inducedulcer model.

In one more embodiment of the present invention, wherein the compositionHF2 reduced the length of hemorrhagic bands to 22.67±4.69 (mm±SE)against alcohol induced gastric ulcer.

In one another embodiment of the present invention, wherein thecomposition HF2 has protection index greater than 80 against pyloricligation induced ulcer.

Brief Description of the Tables

In the tables accompanying the specification,

Table 1 represents the effect of the herbal composition HF2 prepared inaccordance with one of the embodiments of the present invention and astandard drug “Omeprazole” against Cold Restraint (at 4; C temp, for 2hrs.) induced Ulcer (CRU).

Table 2 represents the effect of the herbal composition HF2 prepared inaccordance with one of the embodiments of the present invention and thestandard drug “Omeprazole” against aspirin induced gastric ulcer.

Table 3 represents the effect of the herbal composition HF2 prepared inaccordance with one of the embodiments of the present invention and thestandard drug “Omeprazole” against alcohol induced gastric ulcer inrats.

Table 4 represents the effect of the herbal composition HF2 prepared inaccordance with one of the embodiments of the present invention and thestandard drug “Omeprazole” against Histamine induced ulcer model.

Table 5 represents the effect of the herbal composition HF2 prepared inaccordance with one of the embodiments of the present invention and astandard drug “Omeprazole” against Pyrolic ligation induced ulcer model.

Table 6 gives the composition of the Herbal composition HF2 prepared inaccordance with one of the embodiments of the present invention.

Table 7 provides the antigastric ulcer activity of herbal compositionsHF3, HF4 and HF5 prepared in accordance with the embodiments of thepresent invention against cold restrained ulcer model, pyloric ligationulcer model and alcohol induced ulcer model.

Table 8 provides the results of the study conducted to evaluate thesynergistic effect of the composition HF2.

Table 9 gives the composition of the Herbal compositions HF3, HF4 andHF5.

The invention is further described with respect to the followingexperiments which are given by way of illustration and therefore shouldnot be construed to limit the scope of the invention in any manner.

Experimental Protocol:

Invivo Experiments:

The Applicants have carried out several experiments under differentinduced ulcer conditions and the effect of the herbal composition werestudied and are tabulated herebelow. The effect of the herbalcomposition has been compared with respect to a known anti-ulcer drug“Omeprazole”.

Experiment 1: Effect on Cold Restraint Ulcers(CRU) Model

Method: Adult rats of either sex, weighing 150-175 Gms were fasted for24 hours with free access to water. The test drugs were administered 45minutes before immobilizing the animals. The rats were immobilized inthe restraint cage at 4° C. in BOD incubator for 2 hrs and weresacrificed immediately after the restraint period. (According to themethod of Senay and Levine 1967). The abdomen was cut opened; stomachwas taken out and incised along the greater curvature to observe thegastric lesions with the help of Magnascope (5× magnification).

The following arbitrary scoring system was used to grade the severityand intensity of the lesions.

-   1. Shedding of epithelium=10-   2. Petechial and frank hemorrhages=20-   3. One or two ulcers=30-   4. More than two ulcers=40-   5. Perforated ulcers=50    The presence of any of these lesions was considered as a positive    ulcerogenic response which has been shown as percentage of rats    showing gastric lesions.

The severity of ulcers is expressed in terms of ulcer index, which isthe mean score of gastric lesions of all the rats in a group which isdefined as:

-   Ulcer Index (U. I.)=Us+Up×10⁻¹-   Where Us=Mean severity of ulcer score and Up-Percentage of animals    with Ulcer incidences.

The percentage protection is calculated as follows:

-   Percentage protection ═(C-T/C)×100.-   Wherein-   C=Number of animals showing ulcer response in control group and-   T=Number of animals showing ulcer response in test group.

The effect of the Herbal Composition of the present invention hereafterreferred to as “HF2” against Cold Restraint Ulcer Model (CRU) is givenin Table 1. The effect of the standard drug “Omeprazole” is also givenin Table 1. TABLE 1 THE EFFECT OF THE HERBAL COMPOSITION “HF2” AND THESTANDARD DRUG “OMEPRAZOLE” AGAINST COLD RESTRAINT ULCER MODEL (CRU).Ulcer severity Percentage of ulcer (type of lesions) incidence (No. ofCompounds Scores (No. of rats showing Mean rats showing and lesions/No.of rats tested) severity of ulcer/total No. of Ulcer Protection Doses 1020 30 40 50 ulcer score rats used) index index Control — 6/10 4/10 — —24 100 (10/10) 12.4 00 CRU CRU + HF2 2/10 2/10 — — — 06  40 (4/10) 4.662.90 (50 mg/Kg, p..o.) CRU + Omeprazole 3/10 2/10 — — — 07  50 (5/10)5.7 54.03 (10 mg/Kg, p.o.)

Inference: Omeprazole showed 54.03% protection where as the compositionHF2 showed 62.90%, protection against gastric ulcer. Thus it is clearthat the composition HF2 provides significantly better protectionagainst cold restraint ulcer model as compared to Omeprazole.

Experiment 2: Effect on Aspirin Induced Gastric Ulcer Model

Method: Gastric ulceration was induced by aspirin according to themethod of Djahanguiri (1969). Aspirin (150 mg/Kg.) was administered perorally as a suspension in gum-acacia and the animal was sacrificed 5 hr.after the aspirin treatment and the ulcer index with protection indexwere calculated. The results of the experiment is tabulated in Table 2.

The effect of the herbal composition HF2 and the standard drug“Omeprazole” against aspirin induced gastric ulcer is given in Table 2.TABLE 2 THE EFFECT OF THE HERBAL COMPOSITION “HF2” AND THE STANDARD DRUG“OMEPRAZOLE” AGAINST ASPIRIN INDUCED GASTRIC ULCER Percentage of Ulcerseverity ulcer (type of lesions) Mean incidence Scores (No. of ratsseverity (No. of rats Compounds showing lesions/No. of showing and ofrats tested) ulcer ulcer/total No. Ulcer Protection Doses 10 20 30 40 50score of rats used) index index Control — 2/6 4/6 — — 26.6  100 (6/6)12.66 00 Aspirin (150 mg/KG, p.o.) Aspirin + HF 2 2/6 2/6 — — — 10..066.7 (4/6) 7.67 39.41 (100 mg/Kg, p.o.) Aspirin + Omeprazole 2/6 2/6 — —— 10.0 66.7 (4/6) 7.67 39.41 (10 mg/Kg, p.o.)

Inference: Both Omeprazole and the composition M showed equal protection(39.41% protection) against aspirin induced ulcer model.

Experiment 3: Effect on Alcohol Induced Gastric Ulcers in Rats

Method: Adult rats of either sex were taken; weighing 150-175 grams werefasted for 24 hours with flee access to water. The test drugs wereadministered (p.o.) 45 minutes before alcohol administration. 1 ml ofchilled absolute alcohol was administered (p.o.) to the rats (Accordingto Wittetal)³. Immediately after 1 hour, the animals were anesthetized,abdomen was cut opened stomach was taken out and incised along thegreater curvature to observe the gastric lesions. The ulcers areexamined under the 5× magnification with the help of magnascope.Absolute ethanol lesions appears as blackish lesions grouped in patchesof varying size, usually parallel to the major axis of the stomach. Thelengths of the lesions are measured and summated to give a total lesionscore, then calculated and expressed in percentage.

The effect of the herbal composition “HF2” and the standard drug“Omeprazole” against alcohol induced gastric ulcer in rats is given inTable 3. TABLE 3 THE EFFECT OF THE HERBAL COMPOSITION “HF2” AND THESTANDARD DRUG “OMEPRAZOLE” AGAINST ALCOHOL INDUCED GASTRIC ULCER IN RATSLength of hemorrhagic Compound bands (mm ± SE) Ethanol control 73.5 ±1.5  HF 2 (100 mg/kg, p.o.) + Ethanol 22.67 ± 4.69  Omeprazole (100mg/kg, p.o.) + 56.0 ± 9.12 Ethanol

Inference: The composition of the present invention showed significantprotection against this model also. The protection provided by thecomposition of the present invention is better than Omeprazole.

Experiment 4: Effect on Histamine Induced Ulcer Model

Method: Animals were fasted for 24 hours with access to water. The drugwas given orally 1 hour prior to the histamine administration. Histaminewas administered in a dose of 0.25 mg/Kg, i.m. at 30 minutesinterval-for 7 times and it induced 100% duodenal ulceration in guineapig (According to the method of Watt and Eagleton 1964)⁴. The animalswere sacrificed after half an hour of last injection under etheranesthesia. The stomach along with duodenum was removed washedthoroughly and examined for the lesions and ulcer index with protectionindex was calculated. The results of the experiment are tabulated inTable 4. The effect of the herbal composition “HF2” and the standarddrug “Omeprazole” against Histamine induced ulcer model is given inTable 4. TABLE 4 THE EFFECT OF THE HERBAL COMPOSITION “HF2” AND THESTANDARD DRUG “OMEPRAZOLE” AGAINST HISTAMINE INDUCED ULCER MODEL Ulcerseverity (type Percentage of of lesions) Scores ulcer incidence (No.Guinea pig Mean (No. of animals showing lesions/No. of severity showingulcer/ Volume of Groups and doses of Guinea pig tested) of ulcer totalNo. of gastric fluid compounds 10 20 30 40 50 score animals used) Ulcerindex % Protection (mL) Ulcer Control Histamine — — 1/3 2/3 — 36.6  100(3/3) 13.66 00 4.33 ± 1.01 (0.25 mg/Kg, i.m.) × 7 Histamine + HF2 (50mg/Kg, — — 1/3 — — 10.0 33.3 (1/3) 4.33 68.3 1.60 ± 0.7  p.o.)Histamine + Omeprazole — 1/3 — — — 6.66 33.3 (1/3) 3.99 70.79 1.0 ± 0.2(10 mg/kg, p.o.)

Inference: In this model, Omeprazole showed 70.79% protection whereasthe composition HF2 showed 68.3% protection. In comparison, thecomposition HF2 provides more or less equal protection.

Experiment 5: Effect on Pyloric Ligation Induced Ulcer Model

Method: Animals were fasted for 24 hours in the raised mesh bottom cagesto prevent coprophagia and were allowed free access to water. Thecontrol group of rats was feed with the vehicle and the experimentalgroups with their respective drugs 45 minutes prior to the ligation. Theanimal was anesthetized, abdomen was cut opened sunder xiphoid process,and the pyloric portion of the stomach was slightly lifted and ligatedavoiding any damage to the adjacent blood vessels (According to themethod of Shay et al. 1945). The animals were stitched and kept for 4hours with free access to water. After 4 hours the animals weresacrificed under ether anesthesia and the stomach was dissected outincised along the greater curvature. The stomach was washed thoroughlyand the ulcer index was scored as per in other ulcer models. The resultsof the experiment are tabulated in Table 5.

The effect of the herbal composition “HF2” and the standard drug“Omeprazole” against Pyloric ligation induced ulcer model is given inTable 5. TABLE 5 EFFECT OF OMEPRAZOLE AND THE HERBAL COMPOSITION HF2AGAINST PYLORIC LIGATION INDUCED ULCER Groups Ulcer Index ProtectionIndex Ligation Control 16.6 0.0 Ligation + HF2 1.65 84.08 Ligation +Omeprazofe 6.6 51.44 (10 mg/Kg, p.o.)

Inference: The composition of the present invention showed betterprotection than Omeprazole in the pyloric ligation induced ulcer model.

Experiment 6: Effect of the Present Composition on Acetylcholine andHistamine Induced Contraction of Guinea-Pig Ileum

Method: A piece of 2-3 cm of the terminal ileum of a freshly killedGuinea pig was suspended in an organ bath containing Tyrode solution at34° C. and bubbled with fresh air. Contraction was induced by submaximalcontraction of acetylcholine chloride (1 [ig/mL) and Histamine (1 ng/mL)and it was recorded on a kymograph (According to the method of Patnaik1992). The composition HF2 (up to 250 ng/mL) did not exert anysignificant influence on isolated tissue preparation for anticholinergic(acetylcholine-induced contraction of Guinea-pig ileum) andFk-anti-histaminic (Histamine induced contraction of Guinea-pig ileum)activity.

Experiment 7: Herbs and Preparation of the Composition

For the purpose of conducting animal experiment all the herbs are washeddried and pulverised. All the herbs are taken in the proportion as shownin Table 6. The whole mixture is blended well and used foradministering.

The components and their proportions of the standard herbal compositionaccording to one embodiment of the present invention are listed in Table6. The part of the herb which is used is also mentioned. The placebopreparation is designed to taste, smell and look like an Ayurvedicherbal composition. TABLE 6 THE COMPOSITION OF THE HERBAL COMPOSITIONHF2 S. No. Name of the plant and its part used Percentage 1. Aloebarbadensis (elio) 6-12% 2. Asperagus racemosus (Tubers) 5-13% 3.Glycyrrhiza glabra (roots) 5-12% 4. Seaamum indicum (seeds) 8-14% 5.Evolvulus aisinodes (whole plant) 5-12% 6. Musa sapientum (unripe fruit)7-14% 7. Trachyaparmum roxburghicinum (fruits) 4-12% 8. Embelia ribes(fruits) 9-14% 9 Coriandrum sativum (fruits) 7-14% 10. Cyclea peltate(root) 6-13% 11 Ferula asafoetida (resin) 8-13%

TABLE 7 ANTIGASTRIC ULCER ACTIVITY OF THE HERBAL COMPOSITIONS HF3, HF4AND HF5 Cold restrained Pyloric ligation Alcohol induced Formulationulcer model model ulcer model HF3 66.69 41.75 86.54 HF4 45.86 17.0 79.42HF5 45.86 62.75 85.75

In order to conduct a study on the synergistic effect, the herbalcomposition HF2 was taken and each component was removed and the effectof the resultant composition against cold restrained gastric ulcer modelwas studied. The results of the experiment thus conducted is tabulatedin Table 8. It was concluded from the above experiments that the batchprepared by the removal of Emblica ribes has shown very good protection.TABLE 8 RESULTS OF THE SYNERGISTIC EFFECT STUDY S. No. Details of BatchUlcer Index 1 HF2 without Aloe barbadensis 26.6 2 HF2 without Asperagusracemosus 11.6 3 HF2 without Glycyrrhiza glabra 15.0 4 HF2 withoutSeamum indicum 20.0 5 HF2 without Evolvulus alisinoides 13.3 6 HF2without Trachyspermum roxhurghianum 20.0 7 HF2 without Embelica ribes8.3 8 HF2 without Coriandrum sativum 10.0 9 HF2 without Cyclea peltata11.66 10 HF2 without Ferula asafetida 13.0 11 HF2 without Musa sapientum20.0

TABLE 9 COMPOSITION OF THE HERBAL COMPOSITIONS HF3, HF4 AND HF5 HF3 HF4HF5 1. Asperagus 1. Asperagus  1. Asperagus    racemosus    racemosus   racemosus 2. Glycyrrhiza glabra 2. Glycyrrhiza glabra  2. Glycyrrhizaglabra 3. Seaamum indicum 3. Seaamum indicum  3. Seaamum indicum 4. Musasapientum 4. Musa sapientum  4. Musa sapientum    and 5. Trachyaparmum5. Trachyaparmum  5. Trachyaparmum    roxburghicinum    roxburghicinum   roxburghicinum All in equal 6. Evolvulus aisinodes  6. Evolvulusalsinodes proportions    and 7. Ferula asafoetida  7. Ferula asafoetidaAll in equal  8. Coriandrum sativum proportions  9. Cyclea peltate and10. Aloe barbadensis All in equal proportions

1. A synergistic herbal composition for the treatment of gastric ulcer,said composition essentially comprising of powdered plant parts ofAsperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientumand Trachyaparmum roxburghicinum and optionally, powdered plant parts ofCyclea peltate, Embelia ribes, Coriandrum sativum Ferula asafoetida,Aloe barbadensis and Evolvulus aisinodes along with one or morepharmaceutically acceptable additives/carriers.
 2. A composition asclaimed in claim 1, wherein the composition comprises powdered plantparts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musasapientum and Trachyaparmum roxburghicinum in equal proportions,optionally along with one or more pharmaceutically acceptableadditives/carriers.
 3. A composition as claimed in claim 1, whereincomposition comprises powdered plant parts of Asperagus racemosus,Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmumroxburghicinum, Evolvulus aisinodes and Ferula asafoetida in equalproportions, optionally along with one or more pharmaceuticallyacceptable additives/carriers.
 4. A composition as claimed in claim 1,wherein the composition comprises powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum,Trachyaparmum roxburghicinum, Evolvulus alsinodes, Ferula asafoetida,Coriandrum sativum, Cyclea peltate and Aloe barbadensis in equalproportions, optionally along with one or more pharmaceuticallyacceptable additives/carriers.
 5. A composition as claimed in claim 1,wherein the composition comprises 5-13 wt. % of powdered plant parts ofAsperagus racemosus, 5-12 wt. % of powdered plant parts of Glycyrrhizaglabra, 8-14 wt. % of powdered plant parts of Seaamum indicum, 7-14 wt.% of powdered plant parts of Musa sapientum, 4-12 wt. % of powderedplant parts of Trachyaparmum roxburghicinum, 6-12 wt. % of powderedplant parts of Aloe barbadensis, 5-12 wt. % of powdered plant parts ofEvolvulus aisinodes, 6-13 wt. % of powdered plant parts of Cycleapeltate 9-14 wt. % of powdered plant parts of Embelia ribes, 7-14 wt. %of powdered plant parts of Coriandrum sativum and 8-13 wt. % of plantparts of Ferula asafoetida, optionally along with one or morepharmaceutically acceptable additives/carriers.
 6. A composition asclaimed in claim 1, wherein the plant part of Trachyaparmumroxburghicinum, Embelia ribes and Coriandrum sativum is fruit.
 7. Acomposition as claimed in claim 1, wherein the plant part of Cycleapeltate and Glycyrrhiza glabra is root.
 8. A composition as claimed inclaim 1, wherein the plant part of Aloe barbadensis is elio.
 9. Acomposition as claimed in claim 1, wherein the plant part of Asperagusracemosus is tuber.
 10. A composition as claimed in claim 1, wherein theplant part of Seaamum indicum is seed.
 11. A composition as claimed inclaim 1, wherein the plant part of Musa sapientum is unripe fruit.
 12. Acomposition as claimed in claim 1, wherein the plant part of Ferulaasafoetida is resin.
 13. A synergistic herbal composition for thetreatment of gastric ulcer, said composition comprising equalproportions of 10 powdered plant parts selected from the groupcomprising of powdered plant parts of Asperagus racemosus, Glycyrrhizaglabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum,Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida,Aloe barbadensis and Evolvulus aisinodes, optionally along with one ormore pharmaceutically acceptable additives/carriers.
 14. A compositionas claimed in claim 13, wherein said composition comprises equalproportions of powdered plant parts of Asperagus racemosus, Glycyrrhizaglabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum,Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida andAloe barbadensis, optionally along with one or more pharmaceuticallyacceptable additives/carriers.
 15. A composition as claimed in claim 13,wherein said composition comprises equal proportions of powdered plantparts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musasapientum, Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes,Coriandrum sativum, Ferula asafoetida and Evolvulus aisinodes,optionally along with one or more pharmaceutically acceptableadditives/carriers.
 16. A composition as claimed in claim 13, whereinsaid composition comprises equal proportions of powdered plant parts ofAsperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musasapientum, Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes,Coriandrum sativum, Aloe barbadensis and Evolvulus aisinodes, optionallyalong with one or more pharmaceutically acceptable additives/carriers.17. A composition as claimed in claim 13, wherein said compositioncomprises equal proportions of powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum,Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Ferulaasafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally alongwith one or more pharmaceutically acceptable additives/carriers.
 18. Acomposition as claimed in claim 13, wherein said composition comprisesequal proportions of powdered plant parts of Asperagus racemosus,Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmumroxburghicinum, Cyclea peltate, Coriandrumn sativum, Ferula asafoetida,Aloe barbadensis and Evolvulus aisinodes, optionally along with one ormore pharmaceutically acceptable additives/carriers.
 19. A compositionas claimed in claim 13, wherein said composition comprises equalproportions of powdered plant parts of Asperagus racemosus, Glycyrrhizaglabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum,Embelia ribes, Coriandrum sativum, Ferula asafoetida, Aloe barbadensisand Evolvulus aisinodes, optionally along with one or morepharmaceutically acceptable additives/carriers.
 20. A composition asclaimed in claim 13, wherein said composition comprises equalproportions of powdered plant parts of Asperagus racemosus, Glycyrrhizaglabra, Seaamum indicum, Musa sapientum, Cyclea peltate, Embelia ribes,Coriandrum sativum, Ferula asafoetida, Aloe barbadensis and Evolvulusaisinodes, optionally along with one or more pharmaceutically acceptableadditives/carriers.
 21. A composition as claimed in claim 13, whereinsaid composition comprises equal proportions of powdered plant parts ofAsperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Trachyaparmumroxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum,Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionallyalong with one or more pharmaceutically acceptable additives/carriers.22. A composition as claimed in claim 13, wherein said compositioncomprises equal proportions of powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Musa sapientum, Trachyaparmumroxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum,Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionallyalong with one or more pharmaceutically acceptable additives/carriers.23. A composition as claimed in claim 13, wherein said compositioncomprises equal proportions of powdered plant parts of Asperagusracemosus, Seaamum indicum, Musa sapientum, Trachyaparmumroxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum,Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionallyalong with one or more pharmaceutically acceptable additives/carriers.24. A composition as claimed in claim 13, wherein said compositioncomprises equal proportions of powdered plant parts of Glycyrrhizaglabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum,Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida,Aloe barbadensis and Evolvulus aisinodes, optionally along with one ormore pharmaceutically acceptable additives/carriers.
 25. A process forthe preparation of the novel synergistic herbal composition for thetreatment of gastric ulcer, said process comprising the steps ofpowdering plant parts essentially selected from Asperagus racemosus,Glycyrrhiza glabra, Seaamum indicum, Musa sapientum and Trachycaparmumroxburghicinum and optionally, selected from Cyclea peltate, Embeliaribes, Coriandrum sativum Ferula asafoetida, Aloe barbadensis andEvolvulus aisinodes, mixing the aforesaid powdered plant parts to obtaina mixture and optionally adding one or more pharmaceutically acceptableadditives/carriers to the above mixture.
 26. A process as claimed inclaim 25, wherein said process comprises the steps of powdering plantparts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musasapientum and Trachyaparmum roxburghicinum, mixing the aforesaid plantparts in equal proportions to obtain a mixture and optionally adding oneor more pharmaceutically acceptable additives/carriers to the abovemixture.
 27. A process as claimed in claim 25, wherein said processcomprises the steps of powdering plant parts of Asperagus racemosus,Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmumroxburghicinum, Evolvulus aisinodes and Ferula asafoetida, mixing theaforesaid plant parts in equal proportions to obtain a mixture andoptionally adding one or more pharmaceutically acceptableadditives/carriers to the above mixture.
 28. A process as claimed inclaim 25, wherein said process comprises steps of powdering plant partsof Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musasapientum, Trachyaparmum roxburghicinum, Evolvulus alsinodes, Ferulaasafoetida, Coriandrum sativum, Cyclea peltate and Aloe barbadensis,mixing the aforesaid plant parts in equal proportions to obtain amixture and optionally adding one or more pharmaceutically acceptableadditives/carriers to the above mixture.
 29. A process as claimed inclaim 25, wherein said process comprises the steps of powdering andmixing 5-13 wt. % of plant parts of Asperagus racemosus, 5-12 wt. % ofplant parts of Glycyrrhiza glabra, 8-14 wt. % of plant parts of Seaamumindicum, 7-14 wt. % of plant parts of Musa sapientum, 4-12 wt. % ofplant parts of Trachyaparmum roxburghicinum, 6-12 wt. % of plant partsof Aloe barbadensis, 5-12 wt. % of plant parts of Evolvulus aisinodes,6-13 wt. % of plant parts of Cyclea peltate 9-14 wt. % of plant parts ofEmbelia ribes, 7-14 wt. % of plant parts of Coriandrumn sativum and 8-13wt. % of plant parts of Ferula asafoetida to obtain a mixture andoptionally adding one or more pharmaceutically acceptableadditives/carriers to the above mixture.
 30. A process as claimed inclaim 25, wherein the plant part of Trachyaparmum roxburghicinum,Embelia ribes and Coriandrum sativum is fruit.
 31. A process as claimedin claim 25, wherein the plant part of Cyclea peltate and Glycyrrhizaglabra is root.
 32. A process as claimed in claim 25, wherein the plantpart of Aloe barbadensis is elio.
 33. A process as claimed in claim 25,wherein the plant part of Asperagus racemosus is tuber.
 34. A process asclaimed in claim 25, wherein the plant part of Seaamum indicum is seed.35. A process as claimed in claim 25, wherein the plant part of Musasapientum is unripe fruit.
 36. A process as claimed in claim 25, whereinthe plant part of Ferula asafoetida is resin.
 37. A method of treatinggastric ulcer in a subject, said method comprising administering aneffective amount of the synergistic herbal composition essentiallycomprising of powdered plant parts of Asperagus racemosus, Glycyrrhizaglabra, Seaamum indicum, Musa sapientum and Trachyaparmum roxburghicinumand optionally, powdered plant parts of Cyclea peltate, Embelia ribes,Coriandrum sativum Ferula asafoetida, Aloe barbadensis and Evolvulusaisinodes along with one or more pharmaceutically acceptableadditives/carriers.
 38. A method as claimed in claim 37, wherein saidmethod comprises administering an effective amount of the synergisticherbal composition comprising of powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Seaamum inidicum, Musa sapientum andTrachyaparmum roxburghicinum in equal proportions, optionally along withone or more pharmaceutically acceptable additives/carriers.
 39. A methodas claimed in claim 37, wherein said method comprises administering aneffective amount of the synergistic herbal composition comprising ofpowdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamumiidicun, Musa sapientum, Trachyaparmum roxburghicinum, Evolvulusaisinodes and Ferula asafoetida in equal proportions, optionally alongwith one or more pharmaceutically acceptable additives/carriers.
 40. Amethod as claimed in claim 37, wherein said method comprisesadministering an effective amount of the synergistic herbal compositioncomprising of powdered plant parts of Asperagus racemosus, Glycyrrhizaglabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum,Evolvulus alsinodes, Ferula asafoetida, Coriandrum sativum, Cycleapeltate and Aloe barbadensis in equal proportions, optionally along withone or more pharmaceutically acceptable additives/carriers.
 41. A methodas claimed in claim 37, wherein said method comprises administering aneffective amount of the synergistic herbal composition comprising 5-13wt. % of powdered plant parts of Asperagus racemosus, 5-12 wt. % ofpowdered plant parts of Glycyrrhiza glabra, 8-14 wt. % of powdered plantparts of Seaamum indicum, 7-14 wt. % of powdered plant parts of Musasapientum, 4-12 wt. % of powdered plant parts of Trachyaparmumroxburghicinum, 6-12 wt. % of powdered plant parts of Aloe barbadensis,5-12 wt. % of powdered plant parts of Evolvulus aisinodes, 6-13 wt. % ofpowdered plant parts of Cyclea peltate 9-14 wt. % of powdered plantparts of Embelia ribes, 7-14 wt. % of powdered plant parts of Coriandrumsativum and 8-13 wt. % of plant parts of Ferula asafoetidain equalproportions, optionally along with one or more pharmaceuticallyacceptable additives/carriers.
 42. A method as claimed in any one of theclaims 37 to 41, wherein the subject is a mammal including human.
 43. Amethod as claimed in any one of the claims 37 to 41, wherein theeffective dosage of the composition per day is in the range of 5 to 15g.
 44. A method as claimed in any one of the claims 37 to 41, whereinthe composition can be in the form of tablets, capsules, syrup and anyother conventional forms.
 45. A method as claimed in any one of theclaims 37 to 41, wherein the composition is administered orally,intra-muscularly, and by any other conventional methods.
 46. A method asclaimed in any one of the claims 37 to 41, wherein the composition maybe used for therapeutic as well as prophylactic treatment of gastriculcer.
 47. A method as claimed in any one of the claims 37 to 41,wherein the subject may be administered a bolus dose or a multiple dose.48. A method of treating gastric ulcer in a subject, said methodcomprising administering an effective amount of the synergistic herbalcomposition comprising equal proportions of 10 powdered plant partsselected from the group comprising of powdered plant parts of Asperagusracemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum,Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Coriandrumsativum, Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes,optionally along with one or more pharmaceutically acceptableadditives/carriers.
 49. A method as claimed in claim 41, wherein thecomposition showed more than 62% protection against cold restraint ulcermodel.
 50. A method as claimed in claim 41, wherein the compositionshowed more than 30% protection against aspirin induced ulcer model. 51.A method as claimed in claim 41, wherein the composition reduced thelength of hemorrhagic bands to 22.67±4.69 (mm±SE) against alcoholinduced gastric ulcer.
 52. A method as claimed in claim 41, wherein thecomposition has protection index greater than 80 against pyloricligation induced ulcer.